EI
SCPH

EAM Investors’s scPharmaceuticals SCPH Stock Holding History

EAM Investors’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-265,528
Closed -$2.71M – 366
2023
Q2 		$2.71M Buy
265,528
+96,207
+57% +$1M 0.5% 67
2023
Q1 		$1.54M Sell
169,321
-33,507
-17% -$245K 0.3% 164
2022
Q4 		$1.45M Buy
+202,828
New +$1.24M 0.3% 150

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

EAM Investors's SCPH Position: Q3 2023 in Review

EAM Investors sold out of scPharmaceuticals (SCPH) in Q3 2023, closing a stake of 265,528 shares — an estimated $2.71M sold.

EAM Investors first reported a position in SCPH in Q4 2022 and held it in 3 quarters. The position peaked at $2.71M in Q2 2023. 73 funds tracked by Wall St. Rank hold SCPH as of Q3 2023.

  • EAM Investors reported no remaining scPharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • EAM Investors sold 265,528 scPharmaceuticals shares in Q3 2023, an estimated $2.71M.
  • EAM Investors first reported a position in scPharmaceuticals in Q4 2022 and held it in 3 quarters.
  • EAM Investors's scPharmaceuticals position peaked at $2.71M in Q2 2023.
  • 73 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2023.

Based on EAM Investors's 13F filing for Q3 2023, filed 13 Nov 2023.